Skip to main content
Erschienen in: International Journal of Hematology 2/2010

01.03.2010 | Original Article

The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0

verfasst von: Ritsuro Suzuki, Shigeki Ohtake, Jin Takeuchi, Masami Nagai, Yoshihisa Kodera, Motohiro Hamaguchi, Shuichi Miyawaki, Takahiro Karasuno, Shigetaka Shimodaira, Ryuzo Ohno, Shigeo Nakamura, Tomoki Naoe

Erschienen in: International Journal of Hematology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Immunological phenotyping of acute leukemia have provided enormous and important information for the classification and lineage determination of leukemia. Forty-nine patients with CD7+ CD56+ acute myeloid leukemia (AML) were analyzed. There were 17 patients of M0, which corresponded to myeloid/NK cell precursor acute leukemia, and 32 patients of AML other than M0 (9 each for M1 and M2, one for M3, 3 for M4, 4 for M5 and 6 for M7). Age distribution was similar between these two groups, but CD7+ CD56+ M0 showed significant male predominance than CD7+ CD56+ M1–M7 (M:F = 15:2 vs. 15:17, P = 0.006). The disease localization and the hematological manifestations were different, showing fewer white blood cell counts and circulating leukemic blasts, less anemia, less thrombocytopenia and more frequent extramedullary involvement in M0 group. The prognosis was poor in both groups, and there was no statistical difference. These findings suggest that extramedullary involvement of myeloid/NK cell precursor acute leukemia is not directly derived from the presence of CD7 and CD56 antigens on leukemic cells. The poor prognosis of CD7+ CD56+ M1–M7 suggests that this phenotype may act as a prognostic factor for AML, but this should be confirmed in further studies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group. Br J Haematol. 1976;33:451–8.CrossRefPubMed Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group. Br J Haematol. 1976;33:451–8.CrossRefPubMed
2.
Zurück zum Zitat Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology & genetics: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology & genetics: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
3.
Zurück zum Zitat Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. Leukemia. 1995;9:1783–6.PubMed Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. Leukemia. 1995;9:1783–6.PubMed
4.
Zurück zum Zitat Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 1997;90:2863–92.PubMed Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 1997;90:2863–92.PubMed
5.
Zurück zum Zitat Haferlach T, Kern W, Schnittger S, Schoch C. Modern diagnostics in acute leukemias. Crit Rev Oncol Hematol. 2005;56:223–34.CrossRefPubMed Haferlach T, Kern W, Schnittger S, Schoch C. Modern diagnostics in acute leukemias. Crit Rev Oncol Hematol. 2005;56:223–34.CrossRefPubMed
6.
Zurück zum Zitat Syrjala M, Anttila VJ, Ruutu T, Jansson SE. Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens. Leukemia. 1994;8:1564–70.PubMed Syrjala M, Anttila VJ, Ruutu T, Jansson SE. Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens. Leukemia. 1994;8:1564–70.PubMed
7.
Zurück zum Zitat San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997;90:2465–70.PubMed San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997;90:2465–70.PubMed
8.
Zurück zum Zitat Bradstock K, Matthews J, Benson E, Page F, Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood. 1994;84:1220–5.PubMed Bradstock K, Matthews J, Benson E, Page F, Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood. 1994;84:1220–5.PubMed
9.
Zurück zum Zitat Legrand O, Perrot JY, Baudard M, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood. 2000;96:870–7.PubMed Legrand O, Perrot JY, Baudard M, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood. 2000;96:870–7.PubMed
10.
Zurück zum Zitat Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res. 2004;28:43–8.CrossRefPubMed Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res. 2004;28:43–8.CrossRefPubMed
11.
Zurück zum Zitat Suzuki R, Yamamoto K, Seto M, et al. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood. 1997;90:2417–28.PubMed Suzuki R, Yamamoto K, Seto M, et al. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood. 1997;90:2417–28.PubMed
12.
Zurück zum Zitat Sanchez MJ, Muench MO, Roncarolo MG, Lanier LL, Phillips JH. Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med. 1994;180:569–76.CrossRefPubMed Sanchez MJ, Muench MO, Roncarolo MG, Lanier LL, Phillips JH. Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med. 1994;180:569–76.CrossRefPubMed
13.
Zurück zum Zitat Shibuya A, Nagayoshi K, Nakamura K, Nakauchi H. Lymphokine requirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 1995;85:3538–46.PubMed Shibuya A, Nagayoshi K, Nakamura K, Nakauchi H. Lymphokine requirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 1995;85:3538–46.PubMed
14.
Zurück zum Zitat Perez SA, Sotiropoulou PA, Gkika DG, et al. A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood. 2003;101:3444–50.CrossRefPubMed Perez SA, Sotiropoulou PA, Gkika DG, et al. A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood. 2003;101:3444–50.CrossRefPubMed
15.
Zurück zum Zitat Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res. 1999;23:615–24.CrossRefPubMed Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res. 1999;23:615–24.CrossRefPubMed
16.
Zurück zum Zitat Suzuki R, Murata M, Kami M, et al. Prognostic significance of CD7+ CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0. Int J Hematol. 2003;77:482–9.CrossRefPubMed Suzuki R, Murata M, Kami M, et al. Prognostic significance of CD7+ CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0. Int J Hematol. 2003;77:482–9.CrossRefPubMed
17.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel M-T, et al. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol. 1991;78:325–9.CrossRefPubMed Bennett JM, Catovsky D, Daniel M-T, et al. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol. 1991;78:325–9.CrossRefPubMed
18.
Zurück zum Zitat Jaffe ES, Harris NL, Stein H, et al. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. Jaffe ES, Harris NL, Stein H, et al. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
19.
Zurück zum Zitat ISCN 2005: an International system for Human Cytogenetic Nomenclature. In: Shaffer LG, Tommerup N, editors. Basal: Karger; 2005. ISCN 2005: an International system for Human Cytogenetic Nomenclature. In: Shaffer LG, Tommerup N, editors. Basal: Karger; 2005.
20.
Zurück zum Zitat Seymour JF, Pierce SA, Kantarjian HM, Keating MI, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 1994;8:823–6.PubMed Seymour JF, Pierce SA, Kantarjian HM, Keating MI, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 1994;8:823–6.PubMed
21.
Zurück zum Zitat Thomas X, Vila L, Campos L, Sabido O, Archimbaud E. Expression N-CAM (CD56) on acute leukemia cells: relationship with disease characteristics and outcome. Leuk Lymphoma. 1995;19:295–300.CrossRefPubMed Thomas X, Vila L, Campos L, Sabido O, Archimbaud E. Expression N-CAM (CD56) on acute leukemia cells: relationship with disease characteristics and outcome. Leuk Lymphoma. 1995;19:295–300.CrossRefPubMed
22.
Zurück zum Zitat Ikushima S, Yoshihara T, Matsumura T, et al. Expression of CD56/NCAM on hematopoietic malignant cells. A useful marker for acute monocytic and megakaryocytic leukemias. Int J Hematol. 1991;54:395–403.PubMed Ikushima S, Yoshihara T, Matsumura T, et al. Expression of CD56/NCAM on hematopoietic malignant cells. A useful marker for acute monocytic and megakaryocytic leukemias. Int J Hematol. 1991;54:395–403.PubMed
23.
Zurück zum Zitat Tallman MS, Neuberg D, Bennett JM, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood. 2000;96:2405–11.PubMed Tallman MS, Neuberg D, Bennett JM, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood. 2000;96:2405–11.PubMed
24.
Zurück zum Zitat Scott AA, Head DR, Kopecky KJ, et al. HLA-DR−, CD33+, CD56+ CD16− myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French–American–British acute myeloid leukemia-M3. Blood. 1994;84:244–55.PubMed Scott AA, Head DR, Kopecky KJ, et al. HLA-DR−, CD33+, CD56+ CD16− myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French–American–British acute myeloid leukemia-M3. Blood. 1994;84:244–55.PubMed
25.
Zurück zum Zitat Girodon F, Carli P-M, Favre B, et al. Acute myeloid leukemia with hypergranular cytoplasm: a differential diagnosis of acute promyelocytic leukemia. Leuk Res. 2000;24:979–82.CrossRefPubMed Girodon F, Carli P-M, Favre B, et al. Acute myeloid leukemia with hypergranular cytoplasm: a differential diagnosis of acute promyelocytic leukemia. Leuk Res. 2000;24:979–82.CrossRefPubMed
26.
Zurück zum Zitat Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood. 1997;90:1643–8.PubMed Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood. 1997;90:1643–8.PubMed
27.
Zurück zum Zitat Murray CK, Estey E, Paietta E, et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol. 1999;17:293–7.PubMed Murray CK, Estey E, Paietta E, et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol. 1999;17:293–7.PubMed
28.
Zurück zum Zitat Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2000;18:1295–300.PubMed Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2000;18:1295–300.PubMed
29.
Zurück zum Zitat Ito S, Ishida Y, Oyake T, et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk Lymphoma. 2004;45:1783–9.CrossRefPubMed Ito S, Ishida Y, Oyake T, et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk Lymphoma. 2004;45:1783–9.CrossRefPubMed
30.
Zurück zum Zitat Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15:1161–4.CrossRefPubMed Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15:1161–4.CrossRefPubMed
31.
Zurück zum Zitat Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica. 2002;87:250–6.PubMed Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica. 2002;87:250–6.PubMed
32.
Zurück zum Zitat Raspadori D, Damiani D, Michieli M, et al. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. Haematologica. 2002;87:1135–40.PubMed Raspadori D, Damiani D, Michieli M, et al. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. Haematologica. 2002;87:1135–40.PubMed
33.
Zurück zum Zitat Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematopathol. 2005;45:51–70.CrossRef Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematopathol. 2005;45:51–70.CrossRef
34.
Zurück zum Zitat Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139:532–44.CrossRefPubMed Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139:532–44.CrossRefPubMed
35.
Zurück zum Zitat Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008;26:66–72.CrossRefPubMed Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008;26:66–72.CrossRefPubMed
36.
Zurück zum Zitat Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null cell phenotype. Blood. 2000;96:2993–3000.PubMed Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null cell phenotype. Blood. 2000;96:2993–3000.PubMed
37.
Zurück zum Zitat Asano N, Suzuki R, Kagami Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol. 2005;29:1284–93.CrossRefPubMed Asano N, Suzuki R, Kagami Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol. 2005;29:1284–93.CrossRefPubMed
38.
Zurück zum Zitat Suzuki R, Suzumiya J, Nakamura S, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 2006;37:425–31.CrossRefPubMed Suzuki R, Suzumiya J, Nakamura S, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant. 2006;37:425–31.CrossRefPubMed
39.
Zurück zum Zitat Tassone P, Gozzini A, Goldmacher V, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901–N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004;64:4629–36.CrossRefPubMed Tassone P, Gozzini A, Goldmacher V, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901–N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004;64:4629–36.CrossRefPubMed
40.
Zurück zum Zitat Ishitsuka K, Jimi S, Goldmacher VS, et al. Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. Br J Haematol. 2008;141:129–31.CrossRefPubMed Ishitsuka K, Jimi S, Goldmacher VS, et al. Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. Br J Haematol. 2008;141:129–31.CrossRefPubMed
Metadaten
Titel
The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0
verfasst von
Ritsuro Suzuki
Shigeki Ohtake
Jin Takeuchi
Masami Nagai
Yoshihisa Kodera
Motohiro Hamaguchi
Shuichi Miyawaki
Takahiro Karasuno
Shigetaka Shimodaira
Ryuzo Ohno
Shigeo Nakamura
Tomoki Naoe
Publikationsdatum
01.03.2010
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 2/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0492-1

Weitere Artikel der Ausgabe 2/2010

International Journal of Hematology 2/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.